Which has higher earnings and valuation, SNN or BDX?

Becton, Dickinson and Company has higher revenue and earnings than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.16B 2.00 $625M N/A N/A Becton, Dickinson and Company $21.84B 2.42 $1.68B $3.32 57.82

Does the media prefer SNN or BDX?

In the previous week, Becton, Dickinson and Company had 25 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 34 mentions for Becton, Dickinson and Company and 9 mentions for Smith & Nephew SNATS. Becton, Dickinson and Company's average media sentiment score of 1.20 beat Smith & Nephew SNATS's score of 0.52 indicating that Becton, Dickinson and Company is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Becton, Dickinson and Company 25 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, IDXX or SNN?

IDEXX Laboratories has higher earnings, but lower revenue than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IDEXX Laboratories $4.30B 10.19 $1.06B $14.22 39.17 Smith & Nephew SNATS $6.16B 2.00 $625M N/A N/A

Does the media favor IDXX or SNN?

In the previous week, IDEXX Laboratories and IDEXX Laboratories both had 9 articles in the media. IDEXX Laboratories' average media sentiment score of 0.98 beat Smith & Nephew SNATS's score of 0.52 indicating that IDEXX Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEXX Laboratories 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Smith & Nephew SNATS 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, DXCM or SNN?

DexCom has higher earnings, but lower revenue than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DexCom $4.66B 7.47 $836.30M $2.53 36.50 Smith & Nephew SNATS $6.16B 2.00 $625M N/A N/A

Does the media prefer DXCM or SNN?

In the previous week, DexCom had 14 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 23 mentions for DexCom and 9 mentions for Smith & Nephew SNATS. DexCom's average media sentiment score of 1.65 beat Smith & Nephew SNATS's score of 0.52 indicating that DexCom is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 22 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Smith & Nephew SNATS 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, SNN or GEHC?

GE HealthCare Technologies has higher revenue and earnings than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.16B 2.00 $625M N/A N/A GE HealthCare Technologies $20.63B 1.64 $2.08B $4.36 17.16

Does the media favor SNN or GEHC?

In the previous week, GE HealthCare Technologies had 6 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 15 mentions for GE HealthCare Technologies and 9 mentions for Smith & Nephew SNATS. GE HealthCare Technologies' average media sentiment score of 0.73 beat Smith & Nephew SNATS's score of 0.52 indicating that GE HealthCare Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GE HealthCare Technologies 6 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, SNN or RMD?

ResMed has lower revenue, but higher earnings than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.16B 2.00 $625M N/A N/A ResMed $5.65B 5.91 $1.52B $10.43 22.21

Does the media favor SNN or RMD?

In the previous week, ResMed had 20 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 29 mentions for ResMed and 9 mentions for Smith & Nephew SNATS. ResMed's average media sentiment score of 1.39 beat Smith & Nephew SNATS's score of 0.52 indicating that ResMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ResMed 23 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Smith & Nephew SNATS (SNN) Competitors

$29.29 +0.25 (+0.86%)

As of 08/21/2026 03:58 PM Eastern

Compare

SNN vs. BDX, IDXX, DXCM, GEHC, and RMD

Should you buy Smith & Nephew SNATS stock or one of its competitors? Smith & Nephew SNATS's main competitors and comparable companies include Becton, Dickinson and Company (BDX), IDEXX Laboratories (IDXX), DexCom (DXCM), GE HealthCare Technologies (GEHC), and ResMed (RMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Smith & Nephew SNATS compare to Becton, Dickinson and Company?

Smith & Nephew SNATS (NYSE:SNN) and Becton, Dickinson and Company (NYSE:BDX) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Smith & Nephew SNATS pays an annual dividend of $0.93 per share and has a dividend yield of 3.2%. Becton, Dickinson and Company pays an annual dividend of $4.20 per share and has a dividend yield of 2.2%. Becton, Dickinson and Company pays out 126.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Becton, Dickinson and Company has raised its dividend for 53 consecutive years.

Becton, Dickinson and Company has higher revenue and earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	2.00	$625M	N/A	N/A
Becton, Dickinson and Company	$21.84B	2.42	$1.68B	$3.32	57.82

25.6% of Smith & Nephew SNATS shares are held by institutional investors. Comparatively, 87.0% of Becton, Dickinson and Company shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by company insiders. Comparatively, 0.4% of Becton, Dickinson and Company shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Becton, Dickinson and Company has a net margin of 4.52% compared to Smith & Nephew SNATS's net margin of 0.00%. Becton, Dickinson and Company's return on equity of 14.79% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
Becton, Dickinson and Company	4.52%	14.79%	6.93%

In the previous week, Becton, Dickinson and Company had 25 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 34 mentions for Becton, Dickinson and Company and 9 mentions for Smith & Nephew SNATS. Becton, Dickinson and Company's average media sentiment score of 1.20 beat Smith & Nephew SNATS's score of 0.52 indicating that Becton, Dickinson and Company is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Becton, Dickinson and Company	25 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Smith & Nephew SNATS currently has a consensus target price of $30.93, suggesting a potential upside of 5.58%. Becton, Dickinson and Company has a consensus target price of $185.67, suggesting a potential downside of 3.27%. Given Smith & Nephew SNATS's higher possible upside, equities research analysts clearly believe Smith & Nephew SNATS is more favorable than Becton, Dickinson and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	2 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Becton, Dickinson and Company	1 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.41

Smith & Nephew SNATS has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, Becton, Dickinson and Company has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

Summary

Becton, Dickinson and Company beats Smith & Nephew SNATS on 12 of the 17 factors compared between the two stocks.

How does Smith & Nephew SNATS compare to IDEXX Laboratories?

IDEXX Laboratories (NASDAQ:IDXX) and Smith & Nephew SNATS (NYSE:SNN) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

IDEXX Laboratories has higher earnings, but lower revenue than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEXX Laboratories	$4.30B	10.19	$1.06B	$14.22	39.17
Smith & Nephew SNATS	$6.16B	2.00	$625M	N/A	N/A

IDEXX Laboratories has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

In the previous week, IDEXX Laboratories and IDEXX Laboratories both had 9 articles in the media. IDEXX Laboratories' average media sentiment score of 0.98 beat Smith & Nephew SNATS's score of 0.52 indicating that IDEXX Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEXX Laboratories	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Smith & Nephew SNATS	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IDEXX Laboratories currently has a consensus target price of $747.00, suggesting a potential upside of 34.13%. Smith & Nephew SNATS has a consensus target price of $30.93, suggesting a potential upside of 5.58%. Given IDEXX Laboratories' stronger consensus rating and higher possible upside, equities research analysts clearly believe IDEXX Laboratories is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60
Smith & Nephew SNATS	2 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

IDEXX Laboratories has a net margin of 25.03% compared to Smith & Nephew SNATS's net margin of 0.00%. IDEXX Laboratories' return on equity of 71.96% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEXX Laboratories	25.03%	71.96%	33.60%
Smith & Nephew SNATS	N/A	N/A	N/A

87.8% of IDEXX Laboratories shares are owned by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 0.8% of IDEXX Laboratories shares are owned by company insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

IDEXX Laboratories beats Smith & Nephew SNATS on 11 of the 13 factors compared between the two stocks.

How does Smith & Nephew SNATS compare to DexCom?

DexCom (NASDAQ:DXCM) and Smith & Nephew SNATS (NYSE:SNN) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

97.8% of DexCom shares are held by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are held by institutional investors. 0.3% of DexCom shares are held by company insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, DexCom had 14 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 23 mentions for DexCom and 9 mentions for Smith & Nephew SNATS. DexCom's average media sentiment score of 1.65 beat Smith & Nephew SNATS's score of 0.52 indicating that DexCom is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	22 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Smith & Nephew SNATS	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DexCom has higher earnings, but lower revenue than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.66B	7.47	$836.30M	$2.53	36.50
Smith & Nephew SNATS	$6.16B	2.00	$625M	N/A	N/A

DexCom currently has a consensus target price of $88.71, suggesting a potential downside of 3.93%. Smith & Nephew SNATS has a consensus target price of $30.93, suggesting a potential upside of 5.58%. Given Smith & Nephew SNATS's higher probable upside, analysts plainly believe Smith & Nephew SNATS is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89
Smith & Nephew SNATS	2 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

DexCom has a net margin of 20.12% compared to Smith & Nephew SNATS's net margin of 0.00%. DexCom's return on equity of 35.94% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	20.12%	35.94%	14.75%
Smith & Nephew SNATS	N/A	N/A	N/A

DexCom has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

Summary

DexCom beats Smith & Nephew SNATS on 12 of the 15 factors compared between the two stocks.

How does Smith & Nephew SNATS compare to GE HealthCare Technologies?

Smith & Nephew SNATS (NYSE:SNN) and GE HealthCare Technologies (NASDAQ:GEHC) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Smith & Nephew SNATS has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, GE HealthCare Technologies has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

25.6% of Smith & Nephew SNATS shares are owned by institutional investors. Comparatively, 82.1% of GE HealthCare Technologies shares are owned by institutional investors. 1.0% of Smith & Nephew SNATS shares are owned by company insiders. Comparatively, 0.4% of GE HealthCare Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Smith & Nephew SNATS pays an annual dividend of $0.93 per share and has a dividend yield of 3.2%. GE HealthCare Technologies pays an annual dividend of $0.14 per share and has a dividend yield of 0.2%. GE HealthCare Technologies pays out 3.2% of its earnings in the form of a dividend. GE HealthCare Technologies has increased its dividend for 1 consecutive years.

GE HealthCare Technologies has higher revenue and earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	2.00	$625M	N/A	N/A
GE HealthCare Technologies	$20.63B	1.64	$2.08B	$4.36	17.16

In the previous week, GE HealthCare Technologies had 6 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 15 mentions for GE HealthCare Technologies and 9 mentions for Smith & Nephew SNATS. GE HealthCare Technologies' average media sentiment score of 0.73 beat Smith & Nephew SNATS's score of 0.52 indicating that GE HealthCare Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GE HealthCare Technologies	6 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Smith & Nephew SNATS presently has a consensus target price of $30.93, indicating a potential upside of 5.58%. GE HealthCare Technologies has a consensus target price of $77.73, indicating a potential upside of 3.89%. Given Smith & Nephew SNATS's higher probable upside, analysts clearly believe Smith & Nephew SNATS is more favorable than GE HealthCare Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	2 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
GE HealthCare Technologies	0 Sell rating(s)	11 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.48

GE HealthCare Technologies has a net margin of 9.33% compared to Smith & Nephew SNATS's net margin of 0.00%. GE HealthCare Technologies' return on equity of 20.12% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
GE HealthCare Technologies	9.33%	20.12%	5.74%

Summary

GE HealthCare Technologies beats Smith & Nephew SNATS on 12 of the 17 factors compared between the two stocks.

How does Smith & Nephew SNATS compare to ResMed?

Smith & Nephew SNATS (NYSE:SNN) and ResMed (NYSE:RMD) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

Smith & Nephew SNATS currently has a consensus price target of $30.93, suggesting a potential upside of 5.58%. ResMed has a consensus price target of $239.38, suggesting a potential upside of 3.35%. Given Smith & Nephew SNATS's higher possible upside, equities research analysts plainly believe Smith & Nephew SNATS is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	2 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
ResMed	0 Sell rating(s)	10 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.41

Smith & Nephew SNATS pays an annual dividend of $0.93 per share and has a dividend yield of 3.2%. ResMed pays an annual dividend of $2.64 per share and has a dividend yield of 1.1%. ResMed pays out 25.3% of its earnings in the form of a dividend. ResMed has increased its dividend for 13 consecutive years.

In the previous week, ResMed had 20 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 29 mentions for ResMed and 9 mentions for Smith & Nephew SNATS. ResMed's average media sentiment score of 1.39 beat Smith & Nephew SNATS's score of 0.52 indicating that ResMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ResMed	23 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

25.6% of Smith & Nephew SNATS shares are held by institutional investors. Comparatively, 55.0% of ResMed shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by company insiders. Comparatively, 0.7% of ResMed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

ResMed has lower revenue, but higher earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	2.00	$625M	N/A	N/A
ResMed	$5.65B	5.91	$1.52B	$10.43	22.21

ResMed has a net margin of 26.94% compared to Smith & Nephew SNATS's net margin of 0.00%. ResMed's return on equity of 25.58% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
ResMed	26.94%	25.58%	18.89%

Smith & Nephew SNATS has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, ResMed has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

Summary

ResMed beats Smith & Nephew SNATS on 12 of the 17 factors compared between the two stocks.

Get Smith & Nephew SNATS News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNN vs. The Competition

Export

Metric	Smith & Nephew SNATS	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$12.29B	$6.02B	$7.37B	$24.30B
Dividend Yield	3.19%	1.75%	2.53%	3.70%
P/E Ratio	N/A	26.67	272.60	30.31
Price / Sales	2.00	45.38	618.96	19.89
Price / Cash	8.53	33.24	78.62	32.49
Price / Book	2.37	6.23	13.05	6.77
Net Income	$625M	$150.07M	$3.47B	$1.07B
7 Day Performance	-1.83%	0.69%	2.09%	-0.65%
1 Month Performance	-1.77%	8.91%	6.64%	3.38%
1 Year Performance	-21.96%	8.07%	25.02%	14.90%

Smith & Nephew SNATS Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNN Smith & Nephew SNATS	2.2885 of 5 stars	$29.29 +0.9%	$30.93 +5.6%	-22.0%	$12.29B	$6.16B	N/A	16,988	News Coverage
BDX Becton, Dickinson and Company	3.5774 of 5 stars	$183.50 +0.8%	$185.67 +1.2%	-3.8%	$50.44B	$21.84B	55.13	72,000	Positive News
IDXX IDEXX Laboratories	4.6245 of 5 stars	$559.10 +2.4%	$747.00 +33.6%	-13.7%	$44.05B	$4.30B	39.32	11,000
DXCM DexCom	4.3199 of 5 stars	$90.83 +2.3%	$88.71 -2.3%	+12.3%	$34.28B	$4.66B	35.90	11,000	Positive News
GEHC GE HealthCare Technologies	3.6415 of 5 stars	$72.98 +0.8%	$77.73 +6.5%	-0.5%	$32.96B	$20.63B	16.74	54,000	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:SNN) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Smith & Nephew SNATS (SNN) Competitors

SNN vs. BDX, IDXX, DXCM, GEHC, and RMD

How does Smith & Nephew SNATS compare to Becton, Dickinson and Company?

Summary

How does Smith & Nephew SNATS compare to IDEXX Laboratories?

Summary

How does Smith & Nephew SNATS compare to DexCom?

Summary

How does Smith & Nephew SNATS compare to GE HealthCare Technologies?

Summary

How does Smith & Nephew SNATS compare to ResMed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNN vs. The Competition

Smith & Nephew SNATS Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Smith & Nephew SNATS (SNN) Competitors

SNN vs. BDX, IDXX, DXCM, GEHC, and RMD

How does Smith & Nephew SNATS compare to Becton, Dickinson and Company?

Is SNN or BDX a better dividend stock?

Which has higher earnings and valuation, SNN or BDX?

Do institutionals & insiders have more ownership in SNN or BDX?

Is SNN or BDX more profitable?

Does the media prefer SNN or BDX?

Do analysts recommend SNN or BDX?

Which has more volatility & risk, SNN or BDX?

Summary

How does Smith & Nephew SNATS compare to IDEXX Laboratories?

Which has stronger valuation & earnings, IDXX or SNN?

Which has more volatility & risk, IDXX or SNN?

Does the media favor IDXX or SNN?

Do analysts rate IDXX or SNN?

Is IDXX or SNN more profitable?

Do insiders and institutionals hold more shares of IDXX or SNN?

Summary

How does Smith & Nephew SNATS compare to DexCom?

Do institutionals and insiders hold more shares of DXCM or SNN?

Does the media prefer DXCM or SNN?

Which has better valuation & earnings, DXCM or SNN?

Do analysts prefer DXCM or SNN?

Is DXCM or SNN more profitable?

Which has more risk and volatility, DXCM or SNN?

Summary

How does Smith & Nephew SNATS compare to GE HealthCare Technologies?

Which has more volatility and risk, SNN or GEHC?

Do insiders & institutionals believe in SNN or GEHC?

Is SNN or GEHC a better dividend stock?

Which has better earnings & valuation, SNN or GEHC?

Does the media favor SNN or GEHC?

Do analysts recommend SNN or GEHC?

Is SNN or GEHC more profitable?

Summary

How does Smith & Nephew SNATS compare to ResMed?

Do analysts rate SNN or RMD?

Is SNN or RMD a better dividend stock?

Does the media favor SNN or RMD?

Do institutionals & insiders have more ownership in SNN or RMD?

Which has stronger valuation & earnings, SNN or RMD?

Is SNN or RMD more profitable?

Which has more volatility and risk, SNN or RMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNN vs. The Competition

Smith & Nephew SNATS Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools